



2-methylene-19-nor-1 α -hydroxy-17-ene-homopregnacalciferol And Its Uses

[View U.S. Patent No. 7,241,750 in PDF format.](#)

WARF: P09214US

Inventors: Hector DeLuca, Lori Plum, Bulli Padmaja Tadi, Margaret Clagett-Dame

The Invention

This invention discloses 2-methylene-19-nor-17-ene vitamin D analogs, and specifically 2-methylene-19-nor-1 α -hydroxy-17-ene-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders and inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.

Additional Information

For More Information About the Inventors

- [Margaret Clagett-Dame](#)

Tech Fields

- [Therapeutics & Vaccines : Vitamin D](#)

For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847